Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
Xenon XE 133 is an inhaled radioactive gas used as a diagnostic imaging agent for pulmonary ventilation studies. It enables visualization of lung function and airflow patterns in patients with suspected pulmonary disease. The drug works by being inhaled and distributing through the respiratory system, allowing nuclear imaging to assess ventilation defects.
This legacy diagnostic product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting a declining team focused on managing transition rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Xenon XE 133 offers stability in a legacy diagnostic product with minimal job openings (0 linked roles), indicating a small, mature team focused on maintaining market position and managing decline. This role suits professionals seeking deep expertise in diagnostic imaging commercialization or preparing for post-LOE transition strategies, rather than high-growth career acceleration.
Worked on XENON XE 133 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.